Company Profile
Guardant Health Stock Price, News & Catalysts
- Ticker:
- GH
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
161.67 USD (+2.84%)
Close
Last updated: August 17, 2026
17.3B USD
Market cap
Why the stock is moving
As of Aug 17, 2026, GH closed up 2.84% at $161.67. No new same-company headline was identified in the current news window.
Company overview
Business overview
Guardant Health is a liquid-biopsy company focused on oncology diagnostics for screening, therapy selection, and disease monitoring.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Guardant sits in precision diagnostics.
Business Model Characteristics
The business depends on test adoption, reimbursement, clinical utility, and the expansion of liquid biopsy into more use cases.
Position Within the Biotechnology Landscape
Guardant is a leading oncology-diagnostics platform whose stock moves on adoption, reimbursement, and product performance.
Future catalysts
- Guardant Health's catalysts are Shield screening adoption, Reveal MRD traction, and any reimbursement or launch step that widens the oncology-diagnostics franchise. The company improves when screening and monitoring become more routine in clinical workflows.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Guardant Health (GH)?
Guardant Health (GH) most recently closed at 161.67 USD, a +2.84% move versus the previous session.
What is the market cap of Guardant Health (GH)?
Guardant Health currently has a market capitalization of 17.3B USD on BioPharmSignal.
What does Guardant Health do?
Guardant Health is a liquid-biopsy company focused on oncology diagnostics for screening, therapy selection, and disease monitoring.
On which exchange is GH stock listed?
Guardant Health (GH) is associated with NASDAQ, United States, Biopharma.
What is Guardant?
Guardant Health's catalysts are Shield screening adoption, Reveal MRD traction, and any reimbursement or launch step that widens the oncology-diagnostics franchise.
Which conditions is Guardant Health targeting with Guardant?
Guardant Health is associated with oncology based on its company overview and current catalyst commentary.
How does Guardant Health describe recent progress with Guardant?
Guardant Health's catalysts are Shield screening adoption, Reveal MRD traction, and any reimbursement or launch step that widens the oncology-diagnostics franchise.
What is Health?
Guardant Health is a liquid-biopsy company focused on oncology diagnostics for screening, therapy selection, and disease monitoring.